Generate Biomedicines/$GENB
1D1W1MYTD1Y5YMAX
Capital at risk
About Generate Biomedicines
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
- Ticker
- $GENB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 312
- Headquarters
- Somerville, United States
- Website
- generatebiomedicines.com
GENB Metrics
BasicAdvanced
$2.1B
-
-$3.28
-
-
Price and volume
Market cap
$2.1B
52-week high
$22.67
52-week low
$11.00
Average daily volume
1.2M
Financial strength
Current ratio
8.303
Quick ratio
8.076
Long term debt to equity
0.107
Total debt to equity
0.137
Interest coverage (TTM)
-328.93%
Profitability
EBITDA (TTM)
-249.548
Gross margin (TTM)
-807.30%
Net profit margin (TTM)
-897.71%
Operating margin (TTM)
-991.15%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$80,000
Management effectiveness
Valuation
Price to revenue (TTM)
49.545
Price to book
4.5
Price to tangible book (TTM)
4.5
Price to free cash flow (TTM)
-5.37
Free cash flow yield (TTM)
-18.62%
Free cash flow per share (TTM)
-2.98
Growth
What the Analysts think about GENB
Analyst ratings (Buy, Hold, Sell) for Generate Biomedicines stock.
Analyst projections of the future price of Generate Biomedicines stock.
Bulls say / Bears say
Phase 1 pharmacokinetic data for GB-0895 demonstrated dose-proportional PK without target-mediated drug disposition and a mean terminal half-life of ~98 days, supporting further clinical development. (SEC Filing)
Novartis advanced a biologic designed using Generate’s platform into its preclinical pipeline, validating the platform’s utility and unlocking potential milestone and royalty payments. (SEC Filing)
As of June 30, 2026, Generate held $457.4 million in cash, cash equivalents, and marketable securities, providing funding for operations into the first half of 2028 and reducing near-term financing risk. (SEC Filing)
Q2 collaboration revenue declined 37.7% year-over-year to $6.3 million from $10.1 million in Q2 2025, highlighting volatility and potential slowing in its partnership-driven income streams. (TradingView News)
Net loss widened to $67.3 million in Q2 2026 from $64.0 million in Q2 2025, reflecting increasing cash burn as research expenses outpace revenue growth. (TradingView News)
As a clinical-stage company with no approved products and reliance on future Phase 3 readouts for GB-0895 and early Phase 1 trials for GB-4362 and GB-5267, Generate remains several years away from generating commercial product revenue. (Quartr)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
GENB Financial Performance
Revenues and expenses
GENB Earnings Performance
Company profitability
Upcoming events
No upcoming events
GENB News
AllArticlesVideos
Funds containing GENB
Fund name | Fund size | $GENB weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.